Antimicrobial peptides (AMPs) restore skin microbiota balance, restore barrier function and reduce inflammation in patients with AD by selectively inhibiting the growth of S. aureus, blocking the expression of virulence factors, and regulating skin immune response. This evidence concerns the gene ADSL and Alzheimer disease.